Medigene AG
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 3333 01


Public disclosure of inside information according to article 17 MAR

Medigene AG: Discontinuation of MDG1021 development program - Focus on solid tumors

Planegg/Martinsried (pta023/28.01.2021/14:05) - The Executive Management of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, with approval of the Supervisory Board decided today that, consistent with the company's recent decision to focus its development efforts on solid tumors, the MDG1021 development program is to be discontinued.

Recruitment for the Phase I clinical trial of the T cell receptor-modified T cell therapy MDG1021 directed against the antigen HA-1 in patients suffering from relapsed or persistent blood cancers after allogeneic (non-self) hematopoietic stem cell transplantation, which was initiated at the Leiden University Medical Centre (LUMC) in the Netherlands in mid-2020, will be put on hold with immediate effect. Discussions are ongoing with LUMC regarding the potential assumption of the sponsorship role by the LUMC with continuation of the study under LUMC's responsibility and return of the development and commercialization rights to the HA-1-specific TCR acquired from LUMC in November 2018.

The impact of Medigene's discontinuation of the MDG1021 development program will be taken into account when preparing the 2021 financial guidance, which will be published as part of the Annual Report 2020 in March 2021.

emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg/Martinsried
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00 (share)
98.731 Abonnenten
201.966 Meldungen
83.547 Pressefotos


16.08.2022 - 12:45 | SRH AlsterResearch AG
16.08.2022 - 10:25 | aconitas GmbH
16.08.2022 - 10:00 | ISHAP Gebäudedokumentations GmbH
16.08.2022 - 06:10 | pressetext.redaktion
12.08.2022 - 13:27 | pressetext.redaktion